Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.

ABSTRACT:

Background

Dual antiplatelet therapy (DAPT) is recommended for ≥12 months following coronary drug-eluting stents (DES) to reduce risk of major adverse ischemic events. Randomized trials suggest an abbreviated DAPT duration (≤6 months) is adequately protective. However, these trials are individually underpowered to detect differences in rare but serious events such as stent thrombosis (ST).

Objectives

We performed a meta-analysis of published randomized trials to define the impact of abbreviated DAPT (≤6 months) on death, myocardial infarction (MI), stent thrombosis (ST), and bleeding complications compared to standard-duration DAPT (≥12 months).

Methods

Seven randomized controlled trials comparing abbreviated vs. standard DAPT regimens following DES use were identifie

SUBMITTER: Ziada KM 

PROVIDER: S-EPMC4769123 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature